ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$282.79
−0.92%Oct 19, 2026, 08:00 UTC
AbbVie Inc. reported that ABBV-466 achieved higher endoscopic remission rates at Week 12 than anti-IL-23 p19 or anti-α4β7 monotherapy in a Phase 2a Crohn’s disease study, with the treatment difference increasing at Week 24.
Source:Oct 18, 2026, 22:10 UTC
AbbVie Inc. announced that new and updated data from seven oncology assets will be presented at the 2026 ESMO Congress in Madrid from October 23 to 27.
Source:Oct 17, 2026, 21:45 UTC
AbbVie Inc., BRISTOL MYERS SQUIBB CO and Boehringer Ingelheim moved to intervene in the lawsuit over the 340B rebate pilot.
Source:Oct 15, 2026, 20:06 UTC
AbbVie appointed John M. Carethers as a Class II director, effective October 14, 2026.
Oct 12, 2026, 22:45 UTC
AbbVie Inc. shares closed at $281.04, up 1.65% from the previous close.
Source:Oct 8, 2026, 16:50 UTC
The U.S. Food and Drug Administration granted AbbVie Inc.'s Temab-A two Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer.
Source:Oct 7, 2026, 12:30 UTC
The U.S. Food and Drug Administration granted AbbVie Inc.’s Temab-A two Breakthrough Therapy designations.
Source:Oct 7, 2026, 12:30 UTC
The U.S. Food and Drug Administration granted telisotuzumab adizutecan two Breakthrough Therapy Designations, for colorectal cancer and non-small cell lung cancer.
Source:Oct 5, 2026, 22:46 UTC
AbbVie (ABBV) closed at $265.85, up 1.15% from the prior trading session.
Source:Oct 5, 2026, 20:12 UTC
AbbVie Inc. updated its Q3 2026 and FY2026 earnings guidance, citing $216 million in acquired IPR&D and milestones expense for Q3 and $1,251 million for the full year.
Oct 5, 2026, 18:49 UTC
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial showing epcoritamab in combination with R-CHOP achieved statistically significant improvement in progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients, and will engage global regulatory authorities.
Oct 2, 2026, 20:53 UTC
AbbVie said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.
Source:Oct 2, 2026, 15:01 UTC
AbbVie received FDA approval for Juvmo, a new Parkinson's disease pill, with a commercial launch targeted for October 2026.
Source:Oct 1, 2026, 14:00 UTC
AbbVie presented late-breaking Phase 3 Viti-Up-1 and Viti-Up-2 data at the 2026 EADV Congress in Vienna showing continued facial and total body repigmentation with RINVOQ (upadacitinib) in non-segmental vitiligo through week 76.
Source:Oct 1, 2026, 13:15 UTC
AbbVie's stock rose 25.4% over the six months ending October 2026, driven by growth in Skyrizi, Rinvoq and neuroscience drugs despite Humira erosion and competitive pressures.
Source:Oct 1, 2026, 12:00 UTC
AbbVie announced it will host its third-quarter 2026 earnings conference call and report financial results on October 30, 2026.
Source:Sep 30, 2026, 09:52 UTC
AbbVie announced that its investigational drug ABBV-295 showed up to 9.8% weight loss in a Phase 1 clinical trial, demonstrating "meaningful weight reduction."
Sep 30, 2026, 05:30 UTC
AbbVie announced positive primary results from the Phase 2 APEX Part B study of zumilokibart in adults with moderate to severe atopic dermatitis, with all three dose regimens meeting the primary endpoint and the mid-dose selected for Phase 3 development.
Source:Sep 30, 2026, 05:00 UTC
AbbVie announced new clinical and real-world research across its dermatology portfolio, including data for risankizumab, upadacitinib, lutikizumab and zumilokibart, to be presented at the 2026 EADV Congress in Vienna, Austria.
Source:Sep 29, 2026, 13:00 UTC
AbbVie partnered with ValkAI to apply advanced artificial intelligence.
Sep 28, 2026, 20:17 UTC
ADARx Pharmaceuticals, Inc. issued 5,255,542 shares of common stock to AbbVie Inc. in a private placement at $17.00 per share, raising approximately $89.3 million.
Sep 25, 2026, 22:04 UTC
The US Food and Drug Administration approved AbbVie's drug for Parkinson's disease in adults.
Sep 23, 2026, 17:45 UTC
AbbVie, Astex Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly trained the federated AI model AISB-1-Fed on more than 20,000 proprietary protein–ligand structures in collaboration with Columbia University's AlQuraishi lab, achieving 52.1% high-quality interface predictions versus 35.6% for OpenFold3 Preview 2 and 40.9% for Boltz-2.
Source:Sep 22, 2026, 06:00 UTC
The European Commission approved AbbVie's RINVOQ (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis in patients aged two years and older in the European Union.
Source:Sep 21, 2026, 13:54 UTC
AbbVie agreed to purchase shares in a concurrent private placement that would result in AbbVie owning approximately 4.9% of ADARx Pharmaceuticals.
Source:Sep 21, 2026, 12:00 UTC
AbbVie and Iambic announced a multi-year collaboration to apply Iambic's AI platform to accelerate small molecule drug discovery in immunology, neuroscience and oncology.
Source:Sep 18, 2026, 12:30 UTC
AbbVie presented new real-world data supporting the effectiveness of VRAYLAR (cariprazine) in adults with major depressive disorder and bipolar I depression at Psych Congress 2026 in New Orleans.
Source:Sep 17, 2026, 13:45 UTC
Crohn's and Colitis Canada and AbbVie Canada announced the 2026 recipients of the AbbVie IBD Scholarship Program, awarding fifteen students across Canada $5,000 each.
Source:Sep 17, 2026, 12:00 UTC
Allergan Aesthetics, an AbbVie company, announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow dermabrasion treatments in individuals taking medical weight loss medications, presented at the 2026 Science of Skin Summit.
Source:Sep 15, 2026, 12:00 UTC
Allergan Aesthetics announced it will advance scientific dialogue on skin longevity, aging biology and exosome science at the 2026 Science of Skin Summit, including a featured SkinMedica R&D panel introducing the FACTS Principles.
Source:Sep 1, 2026, 12:05 UTC
Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and HA5 Hydra Collagen Facial Mist as new regenerative skincare products in Irvine, California, on September 1, 2026.
Source:
Page 1Next →